Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

InVitae

Biotech & Life Sciences · San Francisco, United States · Founded 2010 · IPO 2015 Unicorn

Bringing comprehensive, affordable, expert genetic insights into mainstream medical care. To read our community guidelines, visit https://t.co/mWqD4UMDer

Valuation
$1.28B
Market cap · 2026
Revenue
$576M
Latest reported FY

Investors

12 investors on InVitae's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Anya Schiess
Series B+ 11 investors entered at this stage
Genomic Health
Redmile Group
Perceptive Advisors
Decheng Capital
Thomas
Rock Springs Capital
OrbiMed
Genesys Capital
Casdin Capital
Wellington Management
Three Leaf Ventures

Global footprint

Where InVitae has talent and traffic

AI talent share
2.7% of workforce is AI talent
(19 of 693 staff)
Core AI60.87%
Other AI131.88%
Non-AI workforce67497.26%
Workforce by country
14 countries with
team presence
🇺🇸 United States95.7%
🇦🇺 Australia0.6%
🇵🇭 Philippines0.6%
🇧🇷 Brazil0.4%
🇷🇸 Serbia0.2%
Top 5 of 14 shown
Web traffic by country
520K monthly visits
across markets
🇺🇸 United States69.8%
🇵🇰 Pakistan8.9%
🇿🇦 South Africa5.8%
🇨🇦 Canada4.6%
🇺🇦 Ukraine4.3%
Top 5 markets shown

Patent intelligence

$60M patent portfolio · 33 active families

Estimated portfolio value
$60M
4.7% of market cap · 45.2× smaller than top peer Illumina ($2.7B)
33 active patent families
Where InVitae innovates Computational biologyBioinformaticsMolecular biologyGenetic variationData mining

Where InVitae concentrates vs peers

Each axis is a top-10 topic across InVitae and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

InVitae's 8 investments and acquisitions.

Every disclosed deal where InVitae appeared as a backer or acquirer, 2017–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

8 deals across InVitae's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where InVitae deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        InVitae's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        8 of 8 deals

        Market sentiment

        What the market is saying about InVitae

        An AI-synthesized read of the highest-engagement posts about InVitae on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See InVitae on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.